In English | En español
Questions About Cancer? 1-800-4-CANCER

Find News Releases

Search For:
Between these dates:

All News Releases

Large study links nut consumption to reduced death rate
NCI Cancer Center News
- In the largest study of its kind, people who ate a daily handful of nuts were 20 percent less likely to die from any cause over a 30-year period than were those who didn’t consume nuts, say scientists from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and the Harvard School of Public Health. Their report, published in the New England Journal of Medicine, contains further good news. The regular nut-eaters were found to be more slender than those who didn’t eat nuts, a finding that should alleviate the widespread worry that eating a lot of nuts will lead to overweight.

Drug strategy blocks a leading driver of cancer
NCI Cancer Center News
- Using a new strategy, researchers from UC San Francisco (home of the UCSF Helen Diller Family Comprehensive Cancer Center) have succeeded in making small molecules that irreversibly target a mutant form of the protein RAS, without binding to the normal form. This feature distinguishes the molecules from all other targeted drug treatments in cancer, according to the researchers. When tested on human lung cancer cells grown in culture, the molecules efficiently killed the RAS-driven cancer cells.

NIH mouse study finds gut microorganisms may determine cancer treatment outcome
NCI Press Release
(Posted: 11/21/2013) - An intact gut commensal microbiota, which is a population of microorganisms living in the intestine, is required for optimal response to cancer therapy, according to a mouse study by scientists at the National Cancer Institute (NCI)

Duke study shows that oral drug may improve survival in men with metastatic prostate cancer
NCI Cancer Center News
- An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.

Worldwide trends show oropharyngeal cancer rates increasing
NCI News Note
(Posted: 11/20/2013) - NCI scientists report that the incidence of oropharyngeal cancer significantly increased during the period 1983-2002 among people in countries that are economically developed. Oropharyngeal cancer occurs primarily in the middle part of the throat behind the mouth, including the base of the tongue, the side and back walls of the throat, and the tonsils.

Obesity found to be major risk factor in developing basal-like breast cancer
NCI Cancer Center News
- In a study published online by the journal Breast Cancer Research and Treatment, a team from the UNC Gillings School of Global Public Health and the UNC Lineberger Comprehensive Cancer Center outlined, in a mouse model, the biological mechanisms where obesity can create a favorable environment for the growth of basal-like breast cancer tumors.

Deletion of any single gene in yeast provokes mutations elsewhere in the genome
NCI Cancer Center News
- Johns Hopkins researchers report that the deletion of any single gene in yeast cells puts pressure on the organism's genome to compensate, leading to a mutation in another gene. Their discovery, which is likely applicable to human genetics because of the way DNA is conserved across species, could have significant consequences for the way genetic analysis is done in cancer and other areas of research, they say. Johns Hopkins is home to the Kimmel Cancer Center.

How a common chemo drug thwarts graft rejection in bone marrow transplants
NCI Cancer Center News
- Results of a study from Johns Hopkins and its Kimmel Cancer Center may explain why a chemotherapy drug called cyclophosphamide prevents graft-versus-host (GVHD) disease in people who receive bone marrow transplants. The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of GVHD. The findings, published online Nov. 13 in Science Translational Medicine, could pave the way for improvements in preventing GVHD and rejection of transplanted bone marrow and new therapies to prevent or treat a relapse of the underlying cancer after a transplant.

Researchers work to improve outcomes of lymphoma patients
NCI Cancer Center News
- Researchers at the University of Nebraska Medical Center (home of the Fred & Pamela Buffett Cancer Center) have discovered that patients with diffuse large B-cell lymphoma don't respond well to the standard drug therapy used to treat this type of cancer if they have high levels of a gene called STAT3. The findings are published in the November issue of the Journal of Clinical Oncology, the medical journal of the American Society for Clinical Oncology.

Hormonal levels affect endometrial cancer drug efficiency
NCI Cancer Center News
- Modulating the hormonal environment in which endometrial cancers grow could make tumors significantly more sensitive to a new class of drugs known as PARP inhibitors, a researcher at UCLA’s Jonsson Comprehensive Cancer Center has shown for the first time. The findings could lead to a novel one-two punch therapy to fight endometrial cancers and provide an alternative option for conventional treatments that, particularly in advanced disease, have limited efficacy.

< Previous  20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40  Next >